Department of Oncology, First Affiliated Hospital, Xi'an Medical University, Xi'an, Shaanxi, P.R. China.
Department of Respiratory Medicine, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
Int J Oncol. 2018 Feb;52(2):321-336. doi: 10.3892/ijo.2017.4214. Epub 2017 Nov 29.
The exploration of the molecular mechanisms and signaling pathways on lung cancer is very important for developing new strategies of diagnosis and treatment to this disease, such as finding valuable lung cancer markers and molecularly targeted therapies. Previously, a number of studies disclose that heat shock protein 90 (Hsp90) is upregulated in cancer cells, tissues and serum of lung cancer patients, and its upregulation intimately correlates with the occurrence, development and outcome of lung cancer. On the contrary, inhibition of Hsp90 can suppress cell proliferation, motility and metastasis of lung cancer and promote apoptosis of lung cancer cells via complex signaling pathways. In addition, a series of Hsp90 inhibitors have been investigated as effective molecular targeted therapy tactics fighting against lung cancer. This review, systematically summarizes the role of Hsp90 in lung cancer, the molecular mechanisms and development of anti-Hsp90 treatment in lung cancer.
探讨肺癌的分子机制和信号通路对于开发新的诊断和治疗策略非常重要,例如寻找有价值的肺癌标志物和分子靶向治疗方法。此前,许多研究表明,热休克蛋白 90(Hsp90)在癌细胞、肺癌患者的组织和血清中上调,其上调与肺癌的发生、发展和结局密切相关。相反,抑制 Hsp90 可以通过复杂的信号通路抑制肺癌细胞的增殖、运动和转移,并促进肺癌细胞的凋亡。此外,一系列 Hsp90 抑制剂已被研究作为有效的分子靶向治疗策略来对抗肺癌。本文系统地总结了 Hsp90 在肺癌中的作用,以及抗 Hsp90 治疗在肺癌中的分子机制和发展。